FDA Approves Labcorp's Companion Diagnostic for Advanced Melanoma

The U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio tissue complete CDx as a companion diagnostic. This diagnostic tool is designed to identify patients with advanced melanoma who have specific BRAF V600E or V600K mutations, making them eligible for targeted therapies. This approval aims to improve access to crucial treatment options for this aggressive form of skin cancer.